Efficacy of bevacizumab by intravitreal route in choroidal neovascular membrane of eye.

Evaluation of effect of intravitreal bevacizumab in choroidal neovascular membrane of eye.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/09/007288

Enrollment

Registered

2016-09-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having Choroidal Neovasuclar membrane

Interventions

Intervention1: patients of choroidal neovascular membrane: at the one month of last injection of bevacizumab visual actuity and ffa done for retinal changes. Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: patiets having choroidal neovascular membrane

Exclusion criteria

Exclusion criteria: Patients who are not giving written and informed consent for participation in the study. Known patient of diabetic retinopathy, hypertensive retinopathy, macular disorder like macular hole macular haemorrhage macular dystrophies Pre-Existing pathology in eye eg. Corneal macular or optic nerve disorder, active infection of any structure of eye. Any Choroidal Pathology.

Design outcomes

Primary

Measure	Time frame
Vision and Intraocular pressure changesTimepoint: after 6 hours, 48 hours and 7 days for any early and late complications	—

Secondary

Measure	Time frame
dye leakge in FFATimepoint: after one month of last injection	—

Countries

India

Contacts

Public ContactDrNeepa R Gohil

govt medical college Bhavnagar

solankineepa@hotmail.com09909978072

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026